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Abstract
Objective: To determine the importance of IgM antibodies against phosphorylcholine (aPC), a
novel protective factor for cardiovascular disease (CVD), in a population with a non-western life
style as compared with a Swedish control group.
Methods and results: Risk factors for cardiovascular disease were determined in a group of 108
individuals aged 40–86 years from New Guinea and 108 age-and sex-matched individuals from a
population based study in Sweden. Antibodies were tested by ELISA. aPC IgM levels were
significantly higher among New Guineans than among Swedish controls (p < 0.0001). This
difference remained significant among both men and women when controlled for LDL and blood
pressure which were lower and smoking which was more prevalent in New Guineans as compared
to Swedish controls (p < 0.0001). aPC IgM was significantly and negatively associated with age and
systolic blood pressure among Swedish controls and with waist circumference among New
Guineans. aPC IgM levels were significantly higher among women than men in both groups. The
proportion of the saturated fatty acid (FA) myristic acid in serum cholesterol esters was negatively
but polyunsaturated eicosapentaenoic acid and also lipoprotein (a) were positively associated with
aPC IgM levels.
Conclusion: IgM-antibodies against PC, which have atheroprotective properties, are higher in a
population from Kitava, New Guinea with a traditional lifestyle, than in Swedish Controls, and
higher among women than men in both populations tested. Such antibodies could contribute to the
low incidence of cardiovascular disease reported from Kitava and could also provide an explanation
as to why women have a later onset of CVD than men.
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Background
The population from Kitava, Trobriand Islands, Papua,
New Guinea, is virtually uninfluenced by the dietary hab-
its and sedentary lifestyle that are common in developed
countries. Even though controlled studies of atherosclero-
sis have not been performed in this population, available
evidence indicates that cardiovascular disease is very
uncommon[1]. Previous studies have indicated that this
difference may be related to clear differences in measure-
ments related to the metabolic syndrome, for example,
BMI, waist circumference, blood pressure, LDL, insulin-
and leptin levels are low among individuals from
Kitava[2,3]. These factors could provide important clues
as to why CVD is largely absent in Kitava. There are also
interesting dietary differences as compared to a Western
population. In Kitava, staple foods include roots, fruit,
fish, coconut and vegetables. Cereals, dairy products, sep-
arated fats and refined carbohydrates, which are major
staples in western countries, are absent.
Recent evidence indicates that atherosclerosis, the main
cause of cardiovascular disease (CVD) is an inflammatory
disease characterized by immune activation in the artery
wall[4,5]. It is therefore of interest to investigate differ-
ences in atherosclerosis-related immune reactivity
between individuals from Kitava and Sweden.
One such factor that could promote inflammation and
immune activation in the artery wall is oxidized low den-
sity lipoprotein (OxLDL). Early studies indicated that
OxLDL can induce activation of monocytes/macro-
phages[6], endothelial cells[6,7] and T cells[8]. OxLDL
promotes inflammation also in immune competent cells
from atherosclerotic lesions[9].
The role of antibodies against OxLDL (aOxLDL) has been
debated[10,11]. It was originally reported that such anti-
bodies where associated with increased risk of atheroscle-
rosis progression and were risk factors for CVD[12,13]. In
contrast, we demonstrated that aOxLDL were decreased in
patients with early signs of CVD-risk as in borderline
hypertension and suggested that aOxLDL was instead a
protection factor[14], a notion supported by other recent
reports[15,16]. The cause of these discrepancies in reports
about the role of aOxLDL is not clear, but one possibility
is that oxLDL is such a complicated compound that aOx-
LDL measurements are difficult to standardize.
Many biological effects of OxLDL are caused by platelet
activating factor (PAF)-like lipids and/or lysophosphati-
dylcholine (LPC) in OxLDL [17-19] where a small
epitope, phosphorylcholine (PC) is a major component
and essential for interaction with the PAF-receptor and
one important scavenger receptor that takes up oxLDL in
macrophages, CD34. PC is also an immunogenic compo-
nent of many bacteria including S Pneumoniae[20].
We recently demonstrated that aPC of IgM subclass is a
protection factor for human atherosclerosis in patients
with hypertension[21]. We here report that IgM aPC are
on average much higher among individuals from Kitava
than among Swedish controls, and higher in women than
in men in both populations. The implications of these
findings are discussed.
Methods
Subjects
Serum samples were obtained from 108 subjects aged 40–
86 years from Kitava, Trobriand Islands, Papua New
Guinea, and from 108 age-matched Swedish population
based control subjects. Both surveys were approved by the
Ethical committee at the University of Lund. The Kitava
study was given ethical approval by the National Medical
Research Advisory Committee of Papua New Guinea
(PNG). It was approved by other PNG national and pro-
vincial bodies and at the community level by the inhabit-
ants and their chiefs.
The Kitavans are primitive horticulturalists who were
essentially uninfluenced by western dietary habits at the
time of the survey in 1990[22]. From a total population of
2300 Kitavans, all subjects older than 50 years (n = 206)
and 20% of those aged 40 ± 49 (n = 41) were eligible for
this study. Informed consent was obtained through per-
sonal contact. Ages were calculated from well known his-
torical events and were considered accurate to within 3
years for most subjects. The acceptance rate for serum
sampling was only 42% and, therefore, self-selected sub-
jects below 50 years were included. These consisted of per-
sons excluded by the random generator but willing to take
part. Individual subjects did not receive payment for their
participation.
The Swedish controls consisted of Caucasians (and very
few immigrants), half of whom were living in the country-
side and the other half in the small town of Skara. The sur-
vey was conducted in 1993–94 among a random sample
from the population census register stratified by age and
sex[23]. Selected residents in Skara were invited to a
health control at the Skara Health Care centre in 1993–94
(baseline examination). From each 10-year age-category
between 40 and 79 years of age 150 male and 150 female
residents, and in the ages 80 years and above 100 male
and 100 female subjects, were selected. Of these 1400
invited subjects, 1109 (80%) participated and completed
a physical examination. For the present study, one subject,
matched for age and sex, was randomly chosen for each of
the 108 Kitavan subjects. In both populations blood sam-
ples were taken before 9.00 a.m. after overnight fasting.Nutrition & Metabolism 2007, 4:7 http://www.nutritionandmetabolism.com/content/4/1/7
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Blood was centrifuged and serum was frozen in liquid
nitrogen within 60 min. Serum samples were stored in -
70°C until analysis.
Clinical, lipid- and urate measurements
Standard methods were used for measurements of weight,
standing height, waist circumference, triceps skinfold
(TSF) thickness, upper mid-arm circumference (MAC)
and serum levels of total cholesterol (TC), high density
lipoprotein cholesterol (HDL), triglycerides (TG) and uric
acid [23-25]. Blood pressure was measured with subjects
in the sitting position. In Kitava, the measurement arm
was kept parallel to the sternum, thus identical to another
Swedish control population [23-25]. In contrast, in the
Skaraborg survey, the measurement arm was at heart level.
From other studies it is known that blood pressure is
lower in the latter position[26]. Arm muscle circumfer-
ence (AMC) was derived using the equation AMC = MAC
- 0.1(π × TSF). TC was measured using a cholesterol-este-
rase/cholesterol-oxidase method with Seronorm Batch
no. 50 (Nyegaard, Oslo, Norway) as a calibrator. HDL was
determined after precipitation of very low density lipo-
protein cholesterol and low density lipoprotein choles-
terol (LDL) with dextran sulphate and magnesium
chloride. TG was analysed using an enzymatic-colorimet-
ric method. Low density lipoprotein cholesterol (LDL)
was estimated according to Friedewald. Serum uric acid
was determined by the uricase-peroxidase method. The
fatty acid composition of serum cholesterol esters was
determined by using gas liquid chromatographic meth-
ods[27]. Lipoprotein(a) (Lp(a)) was measured by the
Pharmacia Apo(a) RIA method as described earlier[24].
Clinical characteristics of the two study populations are
presented in Table 1.
Reagents
Polysorp F96 microtiter immuno-plates were purchased
from Nunc (Roskilde Denmark), PC-BSA (Phosphoryl-
choline-Bovine Serum Albumin) was purchased from Bio-
search Technologies, Inc (Ca, USA).
Determination of IgM antibodies against PC
IgM antibodies to PC-BSA were determined by enzyme-
linked immunosorbent assay (ELISA) essentially as
described[21]. Briefly, pooled serum from medium to
high-titer individuals was used as an internal standard
and tested on every plate. The plateau of antibody binding
was reached with the antigen concentration of 10 μg/ml.
F96 microtiter polysorp plate was therefore coated with
PC-BSA(10 μg/ml) 50 μl/well in PBS. Coated plates were
incubated overnight at 4°C. After five washings with PBS,
the plates were blocked with 2% BSA-PBS for 2 h at room
temperature and washed as described above. Serum sam-
ples were diluted (1:30) in 0.2% BSA-PBS and added at 50
μl/well.
Plates were incubated overnight at 4°C and washed as
described above. Alkaline phosphatase conjugated goat
anti-human IgM (diluted 1:7000 in the sample buffer)
were added at 100 μl/well and incubated at 4°C over-
night. After five washings, color was developed by adding
the alkaline phosphatase substrate (PNPP) at 100 μl/well
and incubating the plates for 60 min at room temperature
in the dark. The plates were read in an ELISA Multiscan
Plus spectrophotometer (Molecular Devices Emax, San
Francisco) at 405 nm. All samples were measured in
duplicates a single assay and the coefficient of variation
was below 10–15%.
Statistical analysis
Variables were tested for normality. Groups with skewed
variables were compared using the non-parametric Mann-
Whitney's U test and categorical variables were compared
using chi-square tests. General linear model (GLM) was
applied using the statistical software SPSS version 12.02
for Windows to test analysis of variance and investigate
group differences and interaction effects of group and gen-
der on aPC IgM levels. Associations between aPC IgM lev-
els and traditional risk factors were determined using
Pearson correlations for normally distributed variables
and Spearman rank correlations for skewed variables. In
addition, linear regression analysis was conducted with
aPC IgM levels as dependent variable. Additional analysis
of co-variance were made for aPC IgM levels while adjust-
ing for the traditional cardiovascular risk factors smoking,
blood pressure (BP), body mass index (BMI), and lipid
levels. Data are presented as means (standard deviation).
The level of statistical significance was set at a value of P <
0.05.
Results
Table 1 presents basic characteristics by group. There were
striking differences between the Kitava population and
the Swedish controls in aPC IgM levels as indicated in
Table 1 and Figure 1. In addition to the significant differ-
ence in aPC IgM levels between the two populations, met-
abolic factors and blood lipids differed significantly with
a more atherogenic profile in the Swedish population. In
contrast, smoking was much more common among New
Guineans (see Table 1).
Correlation analysis between aPC IgM levels and tradi-
tional riskfactors for all participants and for Kitava and
Skaraborg populations separately are presented in Table 2.
Among all studied participants, aPC IgM levels were sig-
nificantly associated with systolic BP levels (r = .27, p <
.001), diastolic BP levels (r = .15, p = .04), and BMI (r = .-
.34, p < .001) and gender (r = .20, p < .01), whereas aPCNutrition & Metabolism 2007, 4:7 http://www.nutritionandmetabolism.com/content/4/1/7
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IgM levels were not significantly related to total choles-
terol, LDL or triglyceride levels. When separating the
groups, significant associations were only found between
aPC IgM and waist in the Kitava population (r = -.21, p =
.03), and between aPC IgM and age (r = -.22, p = .02) and
SBP (r = -.23, p = .01) in the Swedish population.
A multivariate linear regression including group (Kitava,
Sweden), gender (female, male), presently smoking (no/
yes), systolic BP, BMI and LDL lipid levels and triglycer-
ides was performed and results are presented in Table 3.
Group, gender and systolic BP were independent predic-
tors of aPC IgM levels and together they explained 22% of
the variance of aPC IgM levels.
Table 4 presents the results from interaction analysis of
variance (group by gender). Main effects as well as group
by gender interactions are presented for all variables. As
shown above in Table 1, there was a group main effect on
aPC IgM levels (p < .001), with significantly higher levels
of aPC IgM in both the New Guinea men and women as
compared to the Swedish age and gender matched popu-
lation. There was also a significant effect of gender on aPC
IgM levels (p < .0001), with women having higher aPC
IgM levels as compared to men. There was no significant
interaction between gender and group on aPC IgM levels
(p = .82). There was a significant group effect on systolic
BP (p < .0001), reflecting that New Guineans overall had
lower systolic BP as compared to the Swedish population.
There was no significant main effect of gender on systolic
BP or interaction between gender and group. Diastolic BP
only showed a trendwise difference for the group compar-
ison (p = .07), whereas the gender main effect and inter-
action between gender and group was significant, with
Swedish men having higher diastolic BP as compared to
all other groups (see Table 3). There was a significant
main effect of group on BMI, with the New Guineans hav-
ing significantly lower BMI as compared to the Swedish
population (p < .0001). There was also a main effect of
gender, with women having lower BMI as compared to
the men, whereas the gender × group interaction on BMI
levels did not reach significance. Waist was significantly
lower in the Kitava population (p < .001), and women
had lower waist measure as compared to men (p < .001).
There was a significant main effect of group on both total
cholesterol and LDL levels, with the New Guineans hav-
ing significant lower total cholesterol and LDL levels as
compared the Swedish population. In addition, there was
a main effect of gender as well as a significant interaction
between gender and group, with the New Guinean men
having significant lower total cholesterol and LDL levels
as compared to the other groups. There was no group
effect on HDL levels, but there was a significant gender
effect, with women having higher HDL levels as compared
to men. In addition, there was a significant group effect on
LDL levels, as well as a main gender effect and a gender by
group interaction on LDL levels, with New Guineans hav-
ing lower LDL than the Swedish controls, and overall
women having lower LDL than men and finally New Gui-
nean men having significant lower levels as compared to
all other groups. There was no significant difference
between the groups in triglycerides, nor did the sexes dif-
fer in triglyceride levels. In addition, smoking was signifi-
cantly more common among New Guineans as compared
to the Swedish controls, but there was no main effect on
gender (equal amount of men and women smoked).
However, there was a difference in smoking pattern
between the populations, with women from Sweden
Table 1: Basic characteristics of the study groups. Results are presented as means (SD) or percentages and mmol/L for lipids.
New Guineans (N = 108) Swedish controls (N = 109) P
aPC 981 (283) 740 (295) 0.0001
Age (years) 59.9 (11.1) 59.7 (10.6) 0.85
Sex (% males) 70 70 0.97
SBP (mmHg) 118.6 (18.0) 135.3 (18.2) 0.0001
DBP (mmHg) 70.0 (7.1) 77.3 (9.4) 0.0001
BMI 18.8 (2.2) 25.8 (4.1) 0.0001
Waist 70.9(4.4) 87.2(10.9) 0.0001
Smokers (%) 75.2 24.7 0.0001
Total Cholesterol 5.1 (1.2) 5.8 (0.9) 0.0001
HDL 1.07 (0.15) 1.14 (0.26) 0.04
LDL 3.5 (1.1) 4.0 (0.88) 0.0001
Triglycerides 1.2 (0.46) 1.3 (0.77) 0.10
SBP, systolic blood pressure
DBP, diastolic blood pressure
BMI, body mass index
HDL, high density lipoprotein
LDL, low density lipoproteinNutrition & Metabolism 2007, 4:7 http://www.nutritionandmetabolism.com/content/4/1/7
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Antibody levels against phosphorylcholine (aPC) of IgM subclass, in 108 individuals from New Guinea, Kitava as compared to  109 age and sex matched controls from Skaraborg, Sweden Figure 1
Antibody levels against phosphorylcholine (aPC) of IgM subclass, in 108 individuals from New Guinea, Kitava as compared to 
109 age and sex matched controls from Skaraborg, Sweden. Antibody levels were determined as described in the Methods sec-
tion.
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smoking the least (12%) compared to all other groups,
and women from New Guinea having the highest fre-
quency of smokers (88%).
Analysis of covariance (ANCOVA) was performed to
investigate if the difference in aPC IgM between the New
Guinean and the Swedish group would remain significant
after controlling for the CVD risk factors that were signifi-
cantly different between the groups. The difference in aPC
Igm between the New Guinean and Swedish population
remained significant after adjusting for smoking, systolic
BP, total cholesterol and BMI (F(1, 202) = 5.7, p = .02).
In addition to the 108 individuals from Kitava that were
matched with Swedish controls over 40, we also had
access to an additional 68 Kitavan individuals under the
age of 40. In the whole group from Kitava (comprising of
176 individuals), additional separate analysis and meas-
urements were made, that were not accessible for the
Swedish control population. aPC IgM levels were associ-
ated with waist (r = -.24, p = .002) and upper arm muscu-
larity as represented by AMC (r = -.17, p = .03) and MAC
(r = -.16, p = .04). However, BMI was not significantly
associated with aPC in this population (r = -.10, p = .20).
Among blood lipids, only apo (a) was associated with aPC
IgM (r = .23, p = .004). BP measurements, electrolytes, and
transaminases, were not associated with aPC. There were
significant associations between aPC and certain fatty
acids (FA) in serum cholesterol esters: saturated FA C 14:0
(myristic acid) was negatively (r = -.17, p = .03) but poly-
unsaturated FA C 20:3n-6 was positively associated with
aPC levels (r = .21, p = .007). C14:0 and C20:3n-6 were
significantly (and negatively) associated with each other
(r = -.45, p = 001). Kitavans over the age of 40 had lower
Table 2: Pearson correlation analysis of aPC IgM in association with traditional riskfactors for all study participants (n = 216) and for 
the Kitava (n = 108) and Skaraborg (n = 108) populations separately.
aPC IgM All aPC IgM Kitava aPC IgM Skaraborg
Age (years) -.08 .03 -.22*
SBP (mmHg) -.27*** .001 -.23**
DBP (mmHg) -.15* -.005 -.03
BMI -.34*** -.16 -.05
Smoking (no/yes) .23** .10 -.03
Waist -.36*** -.21* -.12
Total Cholesterol -.11 .06 -.06
HDL -.07 -.18 .10
LDL -.11 .09 -.10
Triglycerides -.03 .14 .01
* p < .05, ** p < .01, ***p < .001
SBP, systolic blood pressure
DBP, diastolic blood pressure
BMI, body mass index
HDL, high density lipoprotein
LDL, low density lipoprotein
Table 3: Multiple regression analysis with aPC IgM as dependent variable and groups (populations) as well as traditional cardiovascular 
risk factors as independent variables
Beta SE of Beta P
Group (New Guinea/Sweden) .16 .07 .02
Gender (male/female) .15 .05 .002
Smoking (no/yes) .01 .05 .78
Age (years) .01 .007 .84
SBP (mmHg) -.004 .001 .01
DBP (mmHg) .005 .003 .07
BMI -.01 .007 .09
LDL -.01 .02 .70
Triglycerides .03 .03 .37
SBP, systolic blood pressure
DBP, diastolic blood pressure
BMI, body mass index
HDL, high density lipoprotein
LDL, low density lipoproteinNutrition & Metabolism 2007, 4:7 http://www.nutritionandmetabolism.com/content/4/1/7
Page 7 of 10
(page number not for citation purposes)
levels of aPC than those under 40 years old (.98(.28) vs
1.07(.23), p = .03) but this association did not quite reach
significance when aPC IgM and age as a continuous varia-
ble was used (r = -.14 p = 0.06). A stepwise regression
model with aPC IgM as dependent variable, showed
Lp(a), waist, and CE 20:3 to be significantly and inde-
pendently associated to aPC IgM.
Discussion
The existence of antibodies against PC in humans has
been known for decades[20], though their clinical role
and function are not well characterized. We recently
reported that aPC IgM were negatively associated with
atherosclerosis development in hypertensives. Further-
more, a high level of aPC of IgM subclass (both at the 75th
and 90th percentile) is associated with a favourable out-
come in ultrasound measurements of atherosclerosis pro-
spectively and thus is a protection factor for
atherosclerosis development in both women and men
with hypertension[21].
We here report that levels of IgM autoantibodies to PC
(aPC) are significantly higher in a population from Kitava,
New Guinea with a traditional lifestyle, as compared to
Swedish controls, matched for age and sex. CVD is virtu-
ally unknown among individuals from Kitava[22], and we
therefore hypothesize that atheroprotective aPC of IgM
subclass may contribute to this.
Oxidized or other forms of modified Low Density Lipo-
protein (OxLDL) are factors that are widely believed to be
of importance in atherogenesis since they promote
immune activtion, inflammation and also apoptosis and
necrosis[10]. We demonstrated in early studies that
OxLDL can activate monocytes/macrophages and
endothelial cells[6] and T cells[8,28]. Further studies have
lead to clarification of one underlying mechanism by
which oxLDL promotes immune activation, namely by
platelet-activating factor (PAF) and PAF-like lipids in
oxLDL which all share PC as a major epitope binding to
the PAF-receptor [17,18,29]. OxLDL is taken up in macro-
phages through specific scavenger receptors, and one
major such receptor, CD 36, has PC as its ligand[30]. Fur-
thermore, PC is known to be immunogenic, present on
important human pathogens like S Pneumoniae[20], and
also apoptotic cells expose this antigen that is normally
cryptic[31]. PC is therefore a highly relevant compound in
atherosclerosis.
In mice, clonally expanded T15 antibodies recognizing PC
which confer protection against lethal infection with S.
Pneumoniae were described already in the 1980s[32].
Such T cell independent antibodies are produced by a B
cell subset, B1 cells, as a part of the innate immune sys-
tem[33].
In mice models of atherosclerosis, aOxLDL and aPC
appear to be raised, and thus these antibodies, could be
described as risk markers, associated with atherosclerosis
in this context[34]. Still, several investigators have dem-
onstrated that immunization with oxLDL [34-36] or S
Pneumoneae[37] attenuates atherosclerosis development
in such models in parallel with further raised aOxLDL and
aPC levels respectively – albeit from an already high level
of such antibodies[34] and passive transfer of aPC amel-
iorates atherosclerosis development in a mouse
model][38].
The cause of these differences between mouse atheroscle-
rosis models and human atherosclerosis is presently
unclear but could indicate that the mouse models for
atherosclerosis only reflect a subfraction of human
Table 4: Results are presented as means (SD) or percentages and mmol/L for lipids.
New Guinean Swedish P
Women (N = 32) Men (N = 76) Women (N = 32) Men (N = 77) Group Gender Group × Gender
aPC IgM 1072 (309) 943(265) 842 (324) 698 (273) .001 .0001 .82
SBP (mmHg) 123.1 (18.8) 116.7 (17.3) 135.6 (18.5) 135.2 (18.2) .0001 .22 .28
DBP (mmHg) 70.2 (8.1) 69.9 (6.7) 73.8 (8.8) 78.8 (9.3) .07 .0001 .04
BMI 17.4 (2.0) 19.4 (2.0) 25.8 (5.3) 25.9 (3.4) .0001 .05 .08
Waist 67.7(4.8) 74.1(4.1) 80.7(12.8) 93.8(9.3) .0001 .0001 .007
Total Cholesterol 5.9 (1.3) 4.7 (0.94) 5.8 (0.93) 5.8 (0.96) .004 .0001 .0001
HDL 1.20 (0.26) 1.0 (0.23) 1.24 (0.31) 1.1 (0.23) .08 .001 .50
LDL 4.16 (1.16) 3.2 (0.90) 4.0 (0.84) 4.1 (0.90) .004 .0001 .0001
Triglycerides 1.30 (0.52) 1.16 (0.44) 1.23 (0.53) 1.38 (0.79) .38 .92 .10
Smoking (%) 88 70 12 30 .001 .98 .008
SBP, systolic blood pressure
DBP, diastolic blood pressure
BMI, body mass index
HDL, high density lipoprotein
LDL, low density lipoproteinNutrition & Metabolism 2007, 4:7 http://www.nutritionandmetabolism.com/content/4/1/7
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atherosclerosis. Even though mouse models of atheroscle-
rosis have increased our knowledge about the role of the
immune system in atherosclerosis, they do not develop
the same type of CVD with atherothrombosis and plaque
rupture as humans[39].
In humans the role of aPC in general and particularly
infectious diseases is unclear, and in one study, aPC was
even reported to be associated prospectively with an
increased risk of death in pneumonia caused by this infec-
tious agent[40].
Since CVD is virtually unknown in Kitava, our findings
suggest that high levels of aPC IgM could function as a
protective factor in these individuals, contributing to pro-
tection against atherosclerosis and CVD. This notion is
also supported by the fact that the high levels of aPC IgM
among New Guineans was independent of other risk fac-
tors that are more prevalent in Swedish controls including
blood pressure, lipids and BMI-related measurements.
Our preliminary experiments indicate that polyclonal
human aPC of IgM subclass can inhibit uptake of oxLDL
in macrophages, suggesting an underlying mechanism by
which aPC IgM could be atheroprotective (unpublished
observation). Other possibilities include inhibition of
proinflammatory effects medicated by PAF-like lipids gen-
erated during LDL-oxidation.
We confirm and extend a previous finding in hyperten-
sives, where men had lower aPC IgM levels than
women[21]. Both among New Guineans and Swedish
controls, men had significantly lower levels of aPC IgM as
compared to women. We thus hypothesize that these
findings could be one underlying factor that contributes
to the lower risk of CVD in women as compared to men
of similar age.
PC is an intriguing molecule from an immunological
point of view, with several properties that could in princi-
ple both promote and protect against disease depending
on pathogen and type of inflammatory reaction. For
example, PC-exposing compounds could elicit at low
grade chronic inflammation and in principle thus also
contribute to atherosclerosis, while protecting against
more acute infections and inflammation[20,41]. In line
with this, PC-containing filarial nematodes, can achieve
longevity in the infected host by suppressing and modu-
lating the host immune response[42].
The underlying mechanisms that cause the decreased aPC
IgM levels in Sweden (or raised levels in New Guinea,
depending on perspective), could have different non-
mutually exclusive explanations including both life style
factors and underlying genetic variations. However, genet-
ics are less likely to explain the findings, considering the
emergence of cardiovascular disease and diabetes in
neighbouring populations after westernization [43-45]
It should also be noted that the cause of the low antibody
levels against these antigens in individuals with increased
atherosclerosis could be caused by consumption into the
atherosclerotic lesions which are known to contain
OxLDL epitopes, or formation of immune complexes con-
taining PC or OxLDL.
Among life style factors, differences in diet and exposure
to infections are interesting possibilities.
There were some potentially interesting associations
between dietary fat [as measured by serum cholesterol
ester fatty acids (CE-FA)] and aPC IgM levels. The diet in
Kitava is rich in saturated myristic acid which is reported
to raise LDL-levels and which, in our study, was negatively
associated with aPC levels. In contrast a polyunsaturated
FA, dihomo-gama-linolic acid 20:3n-6 was positively
associated with aPC. It could be hypothesized that expo-
sure to easily oxidized FA e g in the gut immune system
could elicit more robust aPC IgM levels, in contrast to sat-
urated FA which are not oxidized. However, a caveat is
that only some and not all FA showed this association pat-
tern and further studies are needed to clarify if these asso-
ciations are of importance. It may be relevant in this
context to consider the fact that serum lipid levels are not
optimal in the Kitavans, and higher than in some other
non-western populations[24]. which partly could be due
to the relatively high intake of saturated FA from coconut.
The apoplipoprotein B to A1 ratio was actually higher in
Kitava than in a Swedish control population analysed at
the same laboratory[24].
There was a strong positive association between aPC IgM
levels and Lp(a), which is interesting, since this lipopro-
tein is known to react with a monoclonal antibody against
oxLDL that also recognized PC, and much PC exposed on
LDL in the circulation is present on Lp(a). Mean levels of
Lp(a) did not differ between Kitava and Sweden[24].
Since this lipoprotein has potentially atherogenic proper-
ties, it is possible that raised levels of Lp(a) promote a
robust immune reaction at least in individuals from
Kitava. Whether such associations are present also in a
Swedish population is not known.
Pathogens exposing immunogenic PC include both bacte-
ria like S Pneumoniae and various forms of nematodes,
and one possibility that deserves further exploration is
that increased exposure to some infections in New Guinea
promoting aPC-related immune response could protect
against atherosclerosis.Nutrition & Metabolism 2007, 4:7 http://www.nutritionandmetabolism.com/content/4/1/7
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Smoking was significantly more prevalent among new
Guineans of both sexes, than in Swedish controls. Ciga-
rette smoking is associated with an increased risk of stroke
and IHD within most westernized populations, but in
countries like Japan and China the prevalence of CVD has
been low, despite extensive smoking. It is therefore possi-
ble that smoking is better tolerated in individuals who are
not exposed to other risk factors.
In summary, our findings indicate that high titers of IgM
antibodies against PC, which we recently described as
being a protective factor for atherosclerosis[21], are more
prevalent among individuals from Kitava, New Guinea
who live a traditional life style, as compared to age and
sex-matched Swedish controls. This could contribute to
the low prevalence of CVD apparently present in Kitava.
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